Get Unlimited Plan at 75% OFF!

Advertisement
logo

Lasa Supergenerics

LASA
Micro Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement

Lasa Supergenerics Share price and Fundamental Analysis

View All Details
View All Details
Lasa Supergenerics Limited was incorporated on March 11, 2016. The Company is primarily engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc.
Company Incorporation2016
ChairmanOmkar P Herlekar
Head QuartersMumbai
Previous NameNA

Key Metrics

Market Cap (Cr)
85.27
PE Ratio
0
Industry P/E
35.07
PEG Ratio
0
ROE
-15.37%
ROCE
-8.4%
ROA
-10.7%
Total Debt (Cr)
20.24
Debt to Equity
0.22
Dividend Yield
0%
EPS
0
Book Value & P/B
18.11 x 0.94
Face Value
10
Outstanding Shares(Cr)
5.01
Current Ratio
1.39
EV to Sales
0.83

Stock Returns

1 Week+0.47%
1 Month-2.99%
6 Months-38.52%
1 Year-25.99%
3 Years-61.59%
5 Years-45.84%

CAGR

1 Year CAGR

Revenue Growth

-19.47%

Net Profit Growth

-43.73%

Operating Profit Growth

-73.64%

Dividend Growth

N/A

Stock Returns CAGR

-25.99%
no_data

No Stocks

Smart Score

1.1
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Profit and Loss Statement

Credit Rating
Director Report
Chairman Report
Auditor Report
Mar 25

Promoters : 53.65%

FIIs : 0.00%

DIIs : 0.00%

Public : 46.35%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 20.66% of holding in March 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Lasa Supergenerics Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Lasa Supergenerics Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Lasa Supergenerics Limited was incorporated on March 11, 2016. The Company is primarily engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc.

The Company is a vertically integrated group spanning the entire veterinary, animal and human healthcare value chain-from discovery-to-delivery, with established credentials in research, manufacturing and global marketing. The Company is a veterinary API manufacturing entity, which was acquired in April, 2012. The manufacturing facility is located at Mahad & Chiplun, in the Konkan region of Maharashtra. It specialises in catalyst chemistry' and manufactures anthelmintic / veterinary API products with largest production capabilities and product categories in India.

To efficiently control the supply chain, the Company is fully backward integrated for its key molecules-from discovery research up to full-scale bulk production. The Company's marketing footprint is entrenched across developing markets in multiple countries. Similarly, the group expects to augment its export footprint significantly in width and depth in the future.

The Company announced the launching of 2 new block buster products with all-time strong segment, Oxycozanide. Oxyclozanide is an anthelmintic, used in the treatment and control of fascioliasis a topical worm infection in ruminants mainly domestic animals such as cattle, especially buffalos in farm, sheep, and goats. For this, the Company is setting up capacity in a brown field expansion at its Chiplun unit with a total capacity of 20 MT. It has got huge demand all over the globe as it is manufactured and have strong entry barriers. Likewise, this product fits in product selection criteria, through which the Company is confident of grabbing significant market share.

Due to floods and fire in the company units, the launch of another block buster product was deferred and commercialization of Oxyclozanide prolonged for some time to accommodate existing products in the company. The company received WHO Certificate of Good Manufacturing Practices from the Food and Drug Administration authorities for its manufacturing facility situated at Khed, Ratnagiri. The Company has alliances with leading Indian and global animal health care conglomerates and uses Good Manufacturing Practice (GMP) and world-class technologies in its operations. The Company is managed by a consortium of technocrats, including its Chairman and Managing Director Mr. Omkar P. Herlekar who are impelled by passion and propelled by niche innovation. The leadership team, which is guided by these values, is well positioned to lead into the future.

The Company is determined to achieve of becoming a leading force in the niche animal health care solutions. The objective on which it was founded have always inspired sustainable growth through innovation and shall continue to do so. Today, the Company is the leading manufacturer player in veterinary APIs in India, with a well-established brand known for its high-quality products amongst various customers.

Lasa Supergenerics Share Price

Lasa Supergenerics share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Lasa Supergenerics Market Cap

Market capitalization of Lasa Supergenerics indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Lasa Supergenerics is valued compared to its competitors.

Lasa Supergenerics PE Ratio

Lasa Supergenerics PE ratio helps investors understand what is the market value of each stock compared to Lasa Supergenerics 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Lasa Supergenerics PEG Ratio

The PEG ratio of Lasa Supergenerics evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Lasa Supergenerics ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Lasa Supergenerics generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Lasa Supergenerics ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Lasa Supergenerics in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Lasa Supergenerics Total Debt

Total debt of Lasa Supergenerics shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Lasa Supergenerics Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Lasa Supergenerics compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Lasa Supergenerics CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Lasa Supergenerics over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Lasa Supergenerics Technical Analysis

Technical analysis of Lasa Supergenerics helps investors get an insight into when they can enter or exit the stock. Key components of Lasa Supergenerics Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Lasa Supergenerics shares often struggle to rise above due to selling pressure.

Lasa Supergenerics Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Lasa Supergenerics ’s financial health and profitability.

Lasa Supergenerics Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Lasa Supergenerics Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Lasa Supergenerics Financials

The financials of Lasa Supergenerics provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Lasa Supergenerics Profit and Loss Statements

The profit and loss statement of Lasa Supergenerics highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Lasa Supergenerics .

Lasa Supergenerics Balance Sheet

The balance sheet presents a snapshot of Lasa Supergenerics ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Lasa Supergenerics Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.

Download the App